| Name | Title | Contact Details |
|---|
OneWorld provides quality affordable health care, and individuals are welcome with or without insurance, including Medicaid and Medicare. OneWorld operates 13 clinical locations in Omaha; including the clinics at the Historic Livestock Exchange Campus, OneWorld West, Northwest Omaha, Cass Family Medicine, OneWorld Bellevue, Crossroads to Health and Recovery at Community Alliance, two mobile dental clinics, four school-based health centers and the South Omaha Learning Community Centers. Established in 1970, OneWorld Community Health Centers, in partnership with the community, provides culturally respectful, quality health care with special attention to the underserved. OneWorld is a federally qualified health center (FQHC) and provides comprehensive primary health care, dental, mental health/ substance abuse services, and affordable medications.
CareSite Pharmacy is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Colon And Rectal Surgery Associates Ltd is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Saint Paul, MN. To find more information about Colon And Rectal Surgery Associates Ltd, please visit www.colonrectal.org
Needing healthcare can be hard — getting care shouldnt be. We built Luma Health because we are all patients. We believe it should be easy to see and connect with our doctor. To get the care we need, when we need it. Ours is a new vision aligned around letting systems deliver high-quality healthcare, lower the burden on staff, and provide the modern, mobile-first experience we all deserve.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic